<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205269</url>
  </required_header>
  <id_info>
    <org_study_id>D1883C00004</org_study_id>
    <secondary_id>EudraCT number: 2010-020506-15</secondary_id>
    <nct_id>NCT01205269</nct_id>
  </id_info>
  <brief_title>The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in
      COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose
      phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients
      with chronic obstructive pulmonary disease (COPD)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
    <description>Maximum FEV1 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</measure>
    <time_frame>22 h, 24 h, 26 h</time_frame>
    <description>Trough FEV1 value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post-dose</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
    <description>Average FEV1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC), Peak Effect Over 0 - 24 Hours Post-dose</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
    <description>Maximum FVC value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average systolic blood pressure value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average diastolic blood pressure value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average pulse value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average heart rate value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average QTcF value. QTcF = QT interval corrected for heart rate using Fridericia's formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD8683 Cmax</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 45 min, 1 h, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
    <description>Maximum plasma concentration of AZD8683</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD8683 AUC0-24</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 45 min, 1 h, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
    <description>Area under the AZD8683 plasma concentration curve from 0 to 24 hours</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>First 50 mcg, then 200 mcg, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First 50 mcg, then placebo, then 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First 200 mcg, then placebo, then 50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First 200 mcg, then 50 mcg, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First placebo, then 200 mcg, then 50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First placebo, then 50 mcg, then 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8683, 50 mcg</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>First 50 mcg, then 200 mcg, then placebo</arm_group_label>
    <arm_group_label>First 50 mcg, then placebo, then 200 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then placebo, then 50 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then 50 mcg, then placebo</arm_group_label>
    <arm_group_label>First placebo, then 200 mcg, then 50 mcg</arm_group_label>
    <arm_group_label>First placebo, then 50 mcg, then 200 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>First 50 mcg, then 200 mcg, then placebo</arm_group_label>
    <arm_group_label>First 50 mcg, then placebo, then 200 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then placebo, then 50 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then 50 mcg, then placebo</arm_group_label>
    <arm_group_label>First placebo, then 200 mcg, then 50 mcg</arm_group_label>
    <arm_group_label>First placebo, then 50 mcg, then 200 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8683, 200 mcg</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>First 50 mcg, then 200 mcg, then placebo</arm_group_label>
    <arm_group_label>First 50 mcg, then placebo, then 200 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then placebo, then 50 mcg</arm_group_label>
    <arm_group_label>First 200 mcg, then 50 mcg, then placebo</arm_group_label>
    <arm_group_label>First placebo, then 200 mcg, then 50 mcg</arm_group_label>
    <arm_group_label>First placebo, then 50 mcg, then 200 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of COPD

          -  Current or ex-smokers

          -  FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and
             post-bronchodilator FEV1/FVC &lt; 70%

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal findings at screening examinations

          -  Family history or presence of glaucoma

          -  Need of long term oxygen therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>September 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 13, 2013</results_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>safety</keyword>
  <keyword>inhalation</keyword>
  <keyword>long-acting muscarinic receptor antagonist (LAMA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study has been performed at four centers in Poland. The first subject entered the study on 10 October 2010 and the last subject completed the study on 17 December 2010. The randomised population consisted of 28 patients, 27 completed the study. All patients were included in the analysis of all variables.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>First 50 mcg, Then 200 mcg, Then Placebo</title>
          <description>period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: placebo</description>
        </group>
        <group group_id="P2">
          <title>First 50 mcg, Then Placebo, Then 200 mcg</title>
          <description>period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg</description>
        </group>
        <group group_id="P3">
          <title>First 200 mcg, Then Placebo, Then 50 mcg</title>
          <description>period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg</description>
        </group>
        <group group_id="P4">
          <title>First 200 mcg, Then 50 mcg, Then Placebo</title>
          <description>period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo</description>
        </group>
        <group group_id="P5">
          <title>First Placebo, Then 200 mcg, Then 50 mcg</title>
          <description>period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg</description>
        </group>
        <group group_id="P6">
          <title>First Placebo, Then 50 mcg, Then 200 mcg</title>
          <description>period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 - Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 - Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4 - Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5 - Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all groups randomized to one of 6 sequences of drug or placebo.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" lower_limit="52" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</title>
        <description>Maximum FEV1 value</description>
        <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</title>
          <description>Maximum FEV1 value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.48"/>
                    <measurement group_id="O2" value="1.73" spread="0.47"/>
                    <measurement group_id="O3" value="1.64" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</title>
        <description>Trough FEV1 value</description>
        <time_frame>22 h, 24 h, 26 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</title>
          <description>Trough FEV1 value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.46"/>
                    <measurement group_id="O2" value="1.60" spread="0.46"/>
                    <measurement group_id="O3" value="1.49" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post-dose</title>
        <description>Average FEV1 value</description>
        <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post-dose</title>
          <description>Average FEV1 value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.42"/>
                    <measurement group_id="O2" value="1.54" spread="0.42"/>
                    <measurement group_id="O3" value="1.44" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC), Peak Effect Over 0 - 24 Hours Post-dose</title>
        <description>Maximum FVC value</description>
        <time_frame>0, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC), Peak Effect Over 0 - 24 Hours Post-dose</title>
          <description>Maximum FVC value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.87"/>
                    <measurement group_id="O2" value="3.39" spread="0.81"/>
                    <measurement group_id="O3" value="3.28" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average systolic blood pressure value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average systolic blood pressure value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.7" spread="14.1"/>
                    <measurement group_id="O2" value="131.2" spread="12.0"/>
                    <measurement group_id="O3" value="132.2" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average diastolic blood pressure value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average diastolic blood pressure value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread="7.6"/>
                    <measurement group_id="O2" value="77.5" spread="6.5"/>
                    <measurement group_id="O3" value="77.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average pulse value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average pulse value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="10.5"/>
                    <measurement group_id="O2" value="76.0" spread="11.9"/>
                    <measurement group_id="O3" value="74.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average heart rate value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average heart rate value</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="12.1"/>
                    <measurement group_id="O2" value="75.0" spread="13.4"/>
                    <measurement group_id="O3" value="72.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average QTcF value. QTcF = QT interval corrected for heart rate using Fridericia's formula</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average QTcF value. QTcF = QT interval corrected for heart rate using Fridericia's formula</description>
          <population>Of the 28 randomised patients, 27 completed the study and one discontinued during the last washout period. All 28 randomised patients were included in the analyses of all variables</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.8" spread="22.4"/>
                    <measurement group_id="O2" value="409.1" spread="23.7"/>
                    <measurement group_id="O3" value="411.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD8683 Cmax</title>
        <description>Maximum plasma concentration of AZD8683</description>
        <time_frame>0, 5 min, 15 min, 30 min, 45 min, 1 h, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
        <population>Plasma concentrations were below the LLOQ for all post-dose samples for some patients and treatments. PK parameters for these 3 treatments have been set to missing and are not included in the descriptive statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD8683 Cmax</title>
          <description>Maximum plasma concentration of AZD8683</description>
          <population>Plasma concentrations were below the LLOQ for all post-dose samples for some patients and treatments. PK parameters for these 3 treatments have been set to missing and are not included in the descriptive statistics.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0578" lower_limit="0.008" upper_limit="0.262"/>
                    <measurement group_id="O2" value="0.2791" lower_limit="0.030" upper_limit="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD8683 AUC0-24</title>
        <description>Area under the AZD8683 plasma concentration curve from 0 to 24 hours</description>
        <time_frame>0, 5 min, 15 min, 30 min, 45 min, 1 h, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
        <population>Plasma concentrations were below the LLOQ for all post-dose samples for some patients and treatments. PK parameters for these 3 treatments have been set to missing and are not included in the descriptive statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 50 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 200 mcg</title>
            <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD8683 AUC0-24</title>
          <description>Area under the AZD8683 plasma concentration curve from 0 to 24 hours</description>
          <population>Plasma concentrations were below the LLOQ for all post-dose samples for some patients and treatments. PK parameters for these 3 treatments have been set to missing and are not included in the descriptive statistics.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1872" lower_limit="0.013" upper_limit="0.836"/>
                    <measurement group_id="O2" value="0.8427" lower_limit="0.104" upper_limit="2.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD8683 50 mcg</title>
          <description>1 x AZD8683 Turbuhaler 50mcg + 3x placebo Turbuhaler (dry powder inhaler)</description>
        </group>
        <group group_id="E2">
          <title>AZD8683 200 mcg</title>
          <description>1 x AZD8683 Turbuhaler 50 mcg + 3 x AZD8683 Turbuhaler 50 mcg (dry powder inhaler)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>1 x Placebo Turbuhaler + 3 x Placebo Turbuhaler (dry powder inhaler)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

